Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis

Trial Profile

Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs POL 6014 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2018 According to a Santhera Pharmaceuticals media release, the Cystic Fibrosis Foundation (CFF) is providing funding support for the conduct of the safety trials with POL6014.
    • 24 Oct 2018 According to a Santhera Pharmaceuticals media release, this trial is expected to complete in 2H 2019.
    • 19 Jun 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top